Video

REVIEW UroToday

IBCG AUA 2024 Bladder Cancer Forum VL

Search

Exploring the Complexities of Bladder Cancer Surveillance: Cytology, UroVysion, and Beyond - Komal Pohar & Kelly Bree Details Ashish Kamat engages with Kamal Pohar and Kelly Bree on bladder cancer surveillance. They discuss the ongoing debate about the utility of various urinary markers in monitoring bladder cancer. Dr. Pohar mentions his reliance on cytology, while Dr. Bree adds that she uses cytology and occasionally UroVysion FISH for atypical cases, and also blue light cystoscopy despite its challenges. They both hig...
The Evolving Role of Radical Cystectomy in the Era of Bladder-Sparing Therapies - Sima Porten & Roger Li Details Ashish Kamat hosts Sima Porten and Roger Li to discuss the management of BCG-unresponsive bladder cancer. They emphasize personalized patient care, starting by understanding patients' goals and risk tolerance. Dr. Porten highlights the importance of discussing radical cystectomy as the gold standard while also considering bladder-preserving treatments depending on the patient's disease characteris...
Managing Variant Histology in High-Risk Non-Muscle Invasive Bladder Cancer - Michael Cookson & Paolo Gontero Details Ashish Kamat hosts Paolo Gontero and Michael Cookson to discuss managing high-risk bladder cancer with variant histology. They address the challenges of treating these cases, given the variability in pathology reports and treatment strategies. Dr. Cookson emphasizes treating these patients as high-risk and the importance of proper staging and patient counseling. Dr. Gontero highlights the increase...
To TURBT or Not to TURBT? Evaluating Treatment Options for Recurrent Low-Grade, Intermediate-Risk Bladder Tumors - Sarah Psutka & Param Mariappan Details Ashish Kamat is joined by Paramananthan (Param) Mariappan and Sarah Psutka. They discuss managing patients with low-grade intermediate-risk bladder cancer, focusing on treatment, surveillance, and de-escalation strategies. Dr. Psutka emphasizes the complex decision-making process and the need to understand patient priorities. She highlights the importance of discussing the likelihood of recurrence...
Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla Details Pat Hensley discusses first-line systemic therapy selection for advanced urothelial carcinoma with Karima Oualla and Shilpa Gupta. They highlight cisplatin-based chemotherapy as the traditional mainstay but shift focus to the EV-302 trial, which explores enfortumab vedotin (EV) and pembrolizumab (pembro) as a new first-line combination. Dr. Oualla explains the mechanisms and significant efficacy o...
Defining Standard and Extended Pelvic Lymphadenectomy in Bladder Cancer Surgery - Seth Lerner & Siamak Daneshmand Details Pat Hensley hosts a discussion on the role of pelvic lymphadenectomy during radical cystectomy for muscle invasive bladder cancer. Joining him are Dr. Seth Lerner and Dr. Sia (Siamak) Daneshmand, who contribute their insights on the evolution of surgical guidelines and the integration of new biomarkers in the treatment of advanced bladder cancer. Dr. Lerner elaborates on the standard and extended...
Timing and Rationale for Repeat TURBT: Perspectives on Improving Bladder Cancer Outcomes - Badrinath Konety & Jeremy Teoh Details Ashish Kamat discusses the controversial topic of repeat transurethral resection (reTUR) for high-grade non-muscle-invasive bladder cancer with Badrinath (Badri) Konety and Jeremy Teoh. Dr. Konety highlights the importance of surgeon expertise, noting that experience significantly impacts the quality of the initial TUR. Dr. Teoh emphasizes the need for proper training to avoid the necessity of reT...